Open an account

Oric Pharmaceuticals

ORIC · NASDAQ

$13.78+$1.06 (+8.33%)TodayMarket closed ·
Prev close $12.72

About ORIC

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 104 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Employees
104
Headquarters
South San Francisco, California
Listed
Apr 24, 2020
Sector
Health Care
Industry
Biotechnology
Website
oricpharma.com

ORIC key statistics

Market cap
1.43B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.49M
Volume
2.02M
Open price
$12.79
High today
$14.31
Low today
$12.52
52 Week high
$14.68
52 Week low
$7.23

Oric Pharmaceuticals (ORIC) at a glance

Oric Pharmaceuticals (ORIC) last traded at $13.78, with a market cap of 1.43B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.52 and $14.31. The current price is 10.1% above the day's low and 3.7% below its high.

Volume so far is 2.02M shares, above the average of 1.49M shares a day.

Over the past year Oric Pharmaceuticals has ranged from $7.23 to $14.68, and now sits 88% of the way up that range.

Oric Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.38 per share against an estimate of -$0.3687.

The average analyst price target is $21.34, 54.8% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 12 analyst ratings say Buy
  • Buy91.7%
  • Hold8.3%
  • Sell0.0%
Price target · 15 analystsAvg $21.34
Low
$14.14
Now
$13.78
High
$28.35

ORIC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 14.9% on average.

  1. Q3 FY24: reported -$0.49 per share against an estimate of -$0.488
  2. Q4 FY24: reported -$0.51 per share against an estimate of -$0.5154
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.5213
  4. Q2 FY25: reported -$0.47 per share against an estimate of -$0.4519
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.4132
  6. Q4 FY25: reported -$0.30 per share against an estimate of -$0.3712
  7. Q1 FY26: reported -$0.34 per share against an estimate of -$0.3312
  8. Q2 FY26: reported -$0.38 per share against an estimate of -$0.3687

ORIC news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

  • Press releaseGlobe Newswire

    ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC

Similar companies

Companies in the same industry as Oric Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.